|
|
||||||||
Molecular Diagnostics and Genetics |
1 Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT.
2 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT.
aAddress correspondence to this author at: Department of Pathology, University of Utah Medical School, 50 N. Medical Dr., Salt Lake City, UT 84132. Fax 801-581-6001; e-mail carl.wittwer{at}path.utah.edu.
| Abstract |
|---|
|
|
|---|
Methods: The 27 exons of CFTR were amplified in 37 PCR products under identical conditions. Common variants in 96 blood donors were identified in each exon by high-resolution melting on a LightScanner®. We then performed a subsequent blinded study on 30 samples enriched for disease-causing variants, including all 23 variants recommended by the American College of Medical Genetics and 8 additional, well-characterized variants.
Results: We identified 22 different sequence variants in 96 blood donors, including 4 novel variants and the disease-causing p.F508del. In the blinded study, all 40 disease-causing heterozygotes (29 unique) were detected, including 1 new probable disease-causing variant (c.3500-2A>T). The number of false-positive amplicons was decreased 96% by considering the 6 most common heterozygotes. The melting patterns of most heterozygotes were unique (37 of 40 pairs within the same amplicon), the exceptions being p.F508del vs p.I507del, p.G551D vs p.R553X, and p.W1282X vs c.4002A>G. The homozygotes p.G542X, c.2789 + 5G>A, and c.3849 + 10kbC>T were directly identified, but homozygous p.F508del was not. Specific genotyping of these exceptions, as well as genotyping of the 5T allele of intron 8, was achieved by unlabeled-probe and small-amplicon melting assays.
Conclusions: High-resolution DNA melting methods provide a rapid and accurate alternative for complete CFTR analysis. False positives can be decreased by considering the melting profiles of common variants.
| Introduction |
|---|
|
|
|---|
F508) in cystic fibrosis ranges from as high as 100% in the Faroe Islands of Denmark to as low as 24.5% in Turkey (2). In the Netherlands only 9 mutations occur at frequencies >0.5%, whereas in Greece 22 mutations occur. Several common mutations are specific to ethnic groups, such as p.W1282X among Ashkenazi Jews and c.3120 + 1G>A among native Africans. Genotyping panels are commonly used to screen for cystic fibrosis. The selection of variants is difficult, however, because of ethnic and geographic diversity. In 2001, the American College of Medical Genetics (ACMG)2 recommended a screening panel for the US (3) that included 25 mutations with an estimated frequency of at least 0.1%. Although the screening panel was designed to be panethnic, the estimated detection rates were 97%, 80%, 69%, and 57% for Ashkenazi Jewish, white European, African American, and Hispanic American populations, respectively. With increasing ethnic admixture and limited knowledge of mutation frequency in some regions, creating a suitable panel for ethnically diverse populations is challenging. Three years after their initial recommendation, the ACMG revised their recommendation to include only 23 variants (4).
Complete analysis of CFTR may be used in affected patients when 2 disease alleles are not identified by genotyping assays. Complete gene analysis is seldom recommended as a screening assay because novel variants may be difficult to interpret and can complicate genetic counseling. Furthermore, sequencing remains expensive. Alternatively, scanning techniques have been used to identify CFTR variants, including denaturing gradient gel electrophoresis (5)(6), single-strand conformation polymorphism analysis (7)(8), denaturing HPLC (9)(10), temperature gradient gel electrophoresis (11), and temperature gradient capillary electrophoresis (12). Despite their high degree of accuracy and relatively low cost, the labor-intensive nature of these techniques restricts their use to research and selected reference laboratories.
Recently, high-resolution melting analysis was introduced as a simple, closed-tube, gene scanning technique (13). Sensitivity and specificity appear better than those of denaturing HPLC (14) and approach 100% for PCR products <400 bp (15). All heterozygotes and most homozygotes can be detected without mixing (16)(17), although p.F508del is not distinguished from wild-type (14).
On the basis of the finding that common benign variants can be identified from normal samples (18), we used high-resolution melting to decrease the sequencing burden by using melting patterns to identify and eliminate common variants. We also explored the possibility that most disease-causing variants have unique melting profiles, suggesting that direct genotyping by amplicon melting may be possible. We also aimed to develop specific genotyping assays that can be performed under the same conditions as amplicon scanning for cases in which amplicon melting yielded ambiguous results.
| Materials and Methods |
|---|
|
|
|---|
primers
Primers were designed by use of LightScanner® primer design software (Idaho Technology) and synthesized by the University of Utah core synthesis facility. All 27 exons of CFTR and adjacent intron/exon junctions were amplified in 36 reactions, producing products of 146–322 bp. An additional 206-bp region of intron 19 was amplified to scan for the 3849 + 10kbC>T variant recommended for testing by the ACMG. As much as possible, benign variants within introns were excluded (e.g., the TTGA repeat in intron 6a), whereas most reported disease-causing splice variants were included. The forward primer for exon 9 was designed within the exon boundary to avoid the poly(GT) and poly(T) tracts in intron 8 that are often heterozygous. To maximize sensitivity, exons 4, 7, 13, 15, 17b, 19, and 24 were each split into multiple amplicons. Sequences of the PCR primers and amplicon lengths are listed in Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol53/issue11 .
pcr
PCR was performed in 96-well microtiter plates in 10-µL volumes. Reactions included 25 ng of genomic DNA in 50 mmol/L Tris (pH 8.3) with 2 mmol/L MgCl2, 0.2 mmol/L each deoxynucleoside triphosphate, 500 mg/L BSA, 1x LCGreen® PLUS (Idaho Technology), 0.4 U KlenTaq1TM (AB Peptides), 88 ng of TaqStartTM antibody (Clontech), and 0.5 µmol/L of each primer. To ease assay assembly, the variable reagent was dried in the plate wells and stored. The common PCR reagents were then added at a later time by addition of a master mix. In the studies presented here, template DNA was dried in the plates. However, when only a few samples are studied, it is more convenient to dry the primer sets in different wells.
Reactions were overlaid with 10 µL of mineral oil (Sigma), the plates were centrifuged (1500g for 3–5 min), and PCR was performed in a PTC-200 thermal cycler (Bio-Rad) with an initial denaturation at 95 °C for 5 min, followed by 36 cycles of 95 °C for 30 s, 62 °C for 10 s, and 72 °C for 30 s. To promote heteroduplex formation, samples were subsequently denatured by heating to 95 °C for 30 s and cooled to 15 °C.
melting analysis
After PCR, the plates were centrifuged (1500g for 3–5 min) and imaged in a 96-well LightScanner (Idaho Technology). The plates were heated at 0.1 °C/s, and fluorescence was collected from 60 to 95 °C. Melting curves were analyzed by methods detailed elsewhere (18)(20)(21), either on custom software or with commercial LightScanner software. Briefly, after exponential background subtraction (22), melting curves were normalized between 0% and 100%. Minor temperature differences between samples were corrected by superimposing curves in regions of low fluorescence (2%–5% normalized fluorescence). Normalized and temperature-overlaid curves were viewed on difference plots to magnify variations in melting curve shape. Difference plots were generated by subtracting each curve from the mean wild-type curve, defined as the most common genotype. Clustering of melting curves for genotype identification was performed manually, aided by unbiased, hierarchal clustering using mean absolute difference metrics (18) or commercial LightScanner software on the high sensitivity setting. Predicted melting temperature (Tm) profiles used a Poland-Scheraga model for base-pairing probability profiles (23).
sequencing
The genotype of all variant clusters was determined by standard bidirectional fluorescent sequencing (University of Utah Core Laboratory). Genotype homogeneity within clusters was confirmed by sequencing any samples on the edge of apparent clusters.
preliminary optimization
The 96 apoE DNA samples were used for initial assay optimization and final primer selection. Two previously unreported variants (c.605G>C in exon 4 and c.3891G>A in exon 20) were identified during this initial optimization (Table 1
; data not shown).
|
genotyping assays
Specific genotyping assays were developed for the heterozygotes in exons 10, 11, and 20 that could not be differentiated, for homozygous p.508del and for the 5T allele of the poly(T) tract in intron 8. These assays were designed as either unlabeled probe (24) or small amplicon(16) melting assays, using the same PCR conditions, saturating DNA dye, and melting equipment as the scanning assays.
| Results |
|---|
|
|
|---|
Typical normalized melting plots and plate maps from the random panel are shown in Fig. 1
. All samples in the most common genotype cluster together after normalization and curve overlay. Heterozygous samples have a different shape from that of the common homozygous cluster, with low-temperature deviations resulting from heteroduplexes. When the samples are ordered according to plate position, similar patterns on 8 x 12 plate maps indicate allele associations, such as the haplotype association observed in Fig. 1
.
|
Twenty-two variant alleles were identified in the random panel (Table 1
). The disease-causing p.F508del was detected in 2 samples. No variants were observed in 12 exons and the intron 19 amplicon, and 1 variant was detected in 12 exons, 2 variants in exons 10 and 24, and 3 variants in exon 23. Four variants had an allele fraction >10% (c.1001 + 11C>T, c.1540A>G, c.2789 + 5G>A, and c.4521G>A), and 2 others, >3% (c.125G>C and c.356G> A). Four variants (p.S158T, c.3891G>A, p.L1388V, and p.C1395Y) have not been reported previously, and each was detected in only a single sample.
Melting analysis for a typical exon in the blinded study is shown in Fig. 2
. Thirty normalized melting curves are shown in Fig. 2A
, revealing 2 unique variants. Difference plots provide magnification for easier visualization and discrimination (Fig. 2B
). The 2 variants displace different portions of the melting curve because they occur in different regions of thermal stability. This regional thermal stability can be predicted and plotted against position as displayed in the Tm profile of Fig. 2C
(23). p.G85E is in a region of lower stability and the change in melting curve shape is most distinctive at lower temperatures. In contrast, the p.R75X variant occupies a region of greater thermal stability and exhibits a shape change at higher temperatures.
|
The disease-associated variants tested in the blinded study are shown in Table 2
. All 23 variants recommended for genotyping by the ACMG are included, as well as 8 additional variants associated with disease. The complete genotype of all 30 samples is given in Table 2 in the online Data Supplement.
|
Scanning identified all 40 amplicons with heterozygous disease-causing variants (100% sensitivity for disease-causing variants in the heterozygous state). Of these 40 amplicons, 29 contained unique variants. In addition, scanning identified another 47 amplicons as heterozygous. When the melting profiles of the 6 most common heterozygotes from the random panel were considered, 45 false positives were avoided. The 2 remaining false positives, c.4002A>G in exon 20 and c.4404C>T in exon 24, were less common benign variants. A previously unreported probable splicing variant, c.3500-2A>T, was identified as the 2nd allele of a Coriell sample (NA12960) from a patient with disease.
In addition to heterozygotes, some homozygous variants are detected by high-resolution melting analysis (Fig. 3
). The homozygous c.4521G>A genotype separates from the wild-type, although the magnitude of the deviation is not as great as for the heterozygote (Fig. 3A
). Similarly, the homozygotes of 2 other common variants, c.1001 + 11C>T and c.2694T>G, were easily distinguished (see Figs. 1 and 2 in the online Data Supplement). Furthermore, 3 homozygous disease-causing variants were identified in the blinded study: p.G542X, c.2789 + 5G>A, and c.3849 + 10kbC>T.
|
Not all homozygous variants are distinguishable from each other, however. The 2 exceptions both occurred in exon 10 (Fig. 3B
). Homozygous variants of either the benign c.1540A>G or the disease-causing p.F508del clustered with normal samples. Homozygous p.F508del can be genotyped by mixing with a known genotype (17) either before or after PCR (data not shown) or by unlabeled probe analysis (see Fig. 3 in the online Data Supplement). In total, 6 of 8 homozygous genotypes were detected for a homozygous variant detection sensitivity of 75%.
Most heterozygous variants were distinguishable from each other by the unique shape of their melting profiles. A difference plot of the variants found in exon 11 is shown in Fig. 4
. Six different alleles and 7 unique genotypes are present. Each genotype traces a different path, with the exception of p.G551D and p.R553X. Considering all CFTR amplicons, 37 of 40 pairwise comparisons between different heterozygotes could be distinguished. The exceptions included 3-bp deletions, p.I507del/p.F508del, and 2 single-base variant pairs (p.G551D/p.R553X and p.W1282X/c.4002A>G). Specific genotyping assays that distinguish these variants are detailed in Figs. 3–5 in the online Data Supplement. Fig. 3 in the online Data Supplement demonstrates an unlabeled probe assay to differentiate heterozygous p.I507del from heterozygous p.F508del, as well as homozygous p.F508del from wild-type. Fig. 4 in the online Data Supplement details an unlabeled probe assay to differentiate p.G551D from p.R553X. Fig. 5 in the online Data Supplement describes a small amplicon assay to distinguish the disease-causing variant p.W1282X from the benign variant c.4002A>G.
|
Because the primers for exon 9 avoided the poly(GT) and poly(T) tracts in intron 8, a separate unlabeled probe assay was developed to detect the clinically relevant 5T allele. With a probe complementary to the 5T allele, 7T and 9T alleles form internal bulge loops that result in duplexes with lower melting transitions than the 5T allele (see Fig. 6 in the online Data Supplement).
| Discussion |
|---|
|
|
|---|
High-resolution melting was used to scan CFTR, including intron/exon junctions and a segment of intron 19 to include all ACMG mutations. Thirty-seven amplicons were used with PCR product lengths between 146 and 322 bps. This length restriction was based on a prior study that reported 100% sensitivity and specificity for heterozygous single-base substitutions in amplicons <400 bp (15). In our blinded study, scanning detected all 40 disease-associated heterozygotes for a sensitivity of 100%. However, 47 benign heterozygotes were also detected. In total, 8.7% of the amplicons were heterozygous. If all heterozygous amplicons are sequenced, more benign variants than disease-causing variants are analyzed, even in a population highly enriched for disease-causing variants.
Common benign variants interfere with heteroduplex scanning methods because all variants are detected, whether or not they cause disease. This situation increases the sequencing workload and decreases the utility of scanning. A recent report suggests that analysis of a healthy population can identify common variants by their characteristic melting patterns (18). Therefore, we identified common CFTR variants by scanning a random human DNA panel of 96 samples. Twenty-one apparent benign variants were identified, but only 6 had an allele frequency >0.02. The identity and frequency of variants were similar to those reported previously (30), although 4 novel variants were identified. Using the melting patterns of the 6 most common heterozygotes, we eliminated 45 of 47 benign variants from consideration. Therefore, in our 30 blinded samples, only 2 of 1110 amplicons contained rare benign variants that were not matched to common variants observed in the random population.
The melting profiles obtained by high-resolution melting are often unique to specific variants (13)(31). How a heterozygote alters the melting-curve shape depends on the nature of the heterozygote (i.e., the specific base mismatch), as well as the thermal stability around the variant. For example, Fig. 2
demonstrates the effect of surrounding thermal stability. Although the variants are the same mismatch type (16) and are only 31 bases apart, they are surrounded by regions that differ in thermal stability. As a result, the 2 variants perturb the melting curve at different temperatures and are readily distinguishable. Heterozygotes resulting from deletions and single-base substitutions of different types (16) produce heteroduplexes of varying stability that also uniquely affect the melting curve. In 1 prior study with small amplicons, all 21 random pairs of heterozygotes studied were distinguishable (31).
Not all heterozygous variants produce unique melting curves by amplicon scanning, however. For example, identical nearest neighbor changes may occur at different locations in the same amplicon, such as identical base changes at multiple cysteine residues in the RET protooncogene (32). In this study, 37 of 40 pairs of heterozygotes were distinguishable (93%) when they were in the same amplicon. The exceptions included a pair of 3 base deletions very close to each other (p.I507del and p.F508del), and 2 pairs of single-nucleotide substitutions. The substitutions were 5 bp (p.G551D and p.R553X) and 24 bp (p.W1282X and c.4002A>G) apart, and the variants within each pair were of the same type (16). These exceptions can be genotyped with simple unlabeled probe and/or small amplicon melting assays run under the same conditions as the amplicon-scanning assays (see Figs. 3–5 in the online Data Supplement). Furthermore, an ancillary unlabeled probe assay to detect the 5T allele of the poly(T) tract in intron 8 was developed (see Fig. 6 in the online Data Supplement).
Most scanning technologies do not identify homozygous variants. High-resolution melting is in an exception in that many homozygotes are detected. In this study, 6 of 8 homozygous variants were clearly separated from wild-type, although the melting curve displacement was small compared with heterozygous variants. The detection of homozygous variants by this method implies that the melting curve shape is altered, not just its position along the temperature axis. One of the homozygous variants not detected was the common CFTR benign variant, c.1540A> G. Not detecting this common homozygote simplifies the melting pattern of benign variants and makes it easier to identify disease-causing variants (Fig. 3
). The other homozygote not detected by amplicon scanning is the most common disease-causing variant, p.F508del (14). Many techniques to genotype the p.F508del locus are available [e.g., (19)(33)], and it seems prudent to genotype at least this locus before attempting full gene analysis. Quantitative heteroduplex analysis (17) and unlabeled probes (see Fig. 3 in the online Data Supplement) are attractive options for genotyping because they can use the same PCR and melting protocols used for amplicon scanning. Another option is simultaneous scanning and genotyping with unlabeled probes in the same reaction (34).
There are several practical limitations to scanning by amplicon melting. For highest accuracy, controls must be on the same plate, because between-run variation is greater than within-run variation. Furthermore, because heterozygote scanning is a comparative method, accuracy increases with the number of samples analyzed in a single run. These concerns may be addressed by use of a 384-well plate format to analyze several samples at once, along with at least the 6 most common variants to decrease the sequencing load.
Additional design limitations arise from avoiding the poly(GT) and poly(T) tracts within intron 8 to eliminate heteroduplexes from these repeats. As a result, rare disease-causing variants near the intron 8/exon 9 junction will not be identified. Furthermore, rare splice variants outside our primers or deep within exons will be missed, although we specifically designed an assay to detect the 3849 + 10kbC>T variant. Finally, deletions of one or more exons, estimated to occur at a frequency of 1%–3% in disease-causing chromosomes (35), will not be detected and could make the scanning of hemizygous variants within the deleted area more difficult.
Despite these limitations, high-resolution melting is a simple and rapid method for comprehensive analysis of CFTR, offering speed, low cost, and a high degree of accuracy compared with other scanning techniques. Labor requirements can be decreased by using plates with the oligonucleotides already dried in the wells. The cost of scanning 1 sample as described here is approximately $12 in PCR reagents and disposables, including the saturating DNA dye that accounts for approximately one-sixth of the total cost. One major cost of any scanning method is reflexive sequencing. Decreasing false-positive results by identifying common variants and genotyping disease-causing variants by their melting signatures are 2 options that decrease sequencing requirements. The risk of error when 2 different heterozygotes are in the same amplicon (e.g., misclassifying a rare variant as a common variant or the inability to distinguish 2 disease-causing variants) appears to be approximately 7%. In our blinded study of 30 samples, no misclassification errors were made. If greater accuracy is required, ancillary small amplicon (16)(36) and unlabeled probe (24) genotyping or simultaneous scanning and genotyping with unlabeled probes (34) are options that can be performed on the same platform, either sequentially or in parallel. After DNA purification, PCR amplification and high-resolution melting requires only approximately 2 h on 96- or 384-well plates.
| Acknowledgments |
|---|
Financial disclosures: Aspects of high-resolution melting analysis are licensed from the University of Utah to Idaho Technology. C.T.W. holds equity interest in Idaho Technology.
Acknowledgments: We thank ARUP for providing deidentified clinical samples.
| Footnotes |
|---|
2 Nonstandard abbreviations: ACMG, American College of Medical Genetics; ARUP, Associated Regional and University Pathologists; apoE, apolipoprotein E; Tm, melting temperature. ![]()
| References |
|---|
|
|
|---|
The following articles in journals at HighWire Press have cited this article:
![]() |
E. Lyon and C. T. Wittwer LightCycler Technology in Molecular Diagnostics J. Mol. Diagn., March 1, 2009; 11(2): 93 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhou, R. J. Errigo, H. Lu, M. A. Poritz, M. T. Seipp, and C. T. Wittwer Snapback Primer Genotyping with Saturating DNA Dye and Melting Analysis Clin. Chem., October 1, 2008; 54(10): 1648 - 1656. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-P. Audrezet, A. Dabricot, C. Le Marechal, and C. Ferec Validation of High-Resolution DNA Melting Analysis for Mutation Scanning of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene J. Mol. Diagn., September 1, 2008; 10(5): 424 - 434. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |